Finally, the prevalence of the measured antibodies was compared to the thrombosis occurring in 39.1% of 46 COVID-19 patients leading to no recognizable association, although it was not clear which specific group these 46 patients out of the initial 122 represent; aPL antibodies were therefore rejected as a useful indicator for thrombosis in COVID-19 patients [16]. Here, FASLG is linked to COVID-19.